Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | NQO1 | P15559 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10009619 | 0.92 | HIF1A (0.53) | KDM4EALDH1A1HPGDSMN1; SMN2HIF1A | |
| SCHEMBL2761574 | 0.88 | HIF1A (0.53) | HIF1A | |
| SCHEMBL2762048 | 0.85 | MAOB (0.46) | MAOB | |
| SCHEMBL10010789 | 0.84 | KDM4E (0.54) | KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2761865 | 0.83 | MAOB (0.56) | KDM4EALDH1A1HPGDSMN1; SMN2MAOB | |
| SCHEMBL2761573 | 0.83 | EGLN1 (0.48) | — | |
| SCHEMBL2761676 | 0.83 | HIF1A (0.46) | KDM4EALDH1A1HPGDHIF1ANQO1 | |
| SCHEMBL934940 | 0.82 | HIF1A (0.53) | KDM4EALDH1A1HPGDSMN1; SMN2HIF1A | |
| SCHEMBL2761830 | 0.81 | NQO1 (0.54) | KDM4ESMN1; SMN2MAOBNQO1POLB | |
| SCHEMBL2230004 | 0.80 | HIF1A (0.56) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324405-B2 | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors | FIBROGEN, INC. (US) | 2012-12-04 | — | — | US | claimed |
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. | 2010-12-30 | — | — | US | claimed |
| WO-2009100250-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. (US) | 2009-08-13 | — | — | WO | claimed |
| US-8324405-B2 | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors | FIBROGEN, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2009100250-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | HIF1AN, HIF1A, EGLN2 | KDM4E 550/4885ALDH1A1 202/4885HPGD 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.